A Study for the Neoadjuvant Treatment of Breast Cancer

Due to the unique advantages of albumin-bound paclitaxel, several studies in China and abroad have tried to use albumin-bound paclitaxel for neoadjuvant treatment of breast cancer up to now. However, comparative studies between paclitaxel and docetaxel are still rare, In this study, a prospective, randomized, open-label, multi-center clinical study was conducted to analyse the efficacy and safety of albumin-bound paclitaxel and docetaxel in the neoadjuvant treatment of breast cancer, and to further analyse the efficacy and safety of albumin paclitaxel in combination with chemotherapy for postoperative breast cancer in different subtypes of breast cancer patients, in order to obtain more realistic data and provide new treatment options for breast cancer patients.

NCT Number	NCT05420454
Lead Sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions	Breast Cancer
Enrollment	1,576 participants
Start Date	2022-07-10
Primary Completion	2027-06-10 (estimated)
Study Completion	2027-12-20 (estimated)
Updated on ClinicalTrials.gov	2022-07-01